The PRECiSE 2 trial of certolizumab pegol, a new PEGylated anti-TNF agent, in the treatment of Crohn's disease - An interview with David A Schwartz, 13 June 2007
David A SchwartzVanderbilt University Medical Center, Nashville, TN, USAContext: Certolizumab pegol (CDP 870) is a new anti-tumor necrosis factor (TNF) therapy currently in development for the treatment of Crohn’s disease, rheumatoid arthritis, and psoriasis. Certolizumab pegol is the...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2008
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/08346a070d204e8d80f6d9eaca6f7195 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:08346a070d204e8d80f6d9eaca6f7195 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:08346a070d204e8d80f6d9eaca6f71952021-12-02T02:50:29ZThe PRECiSE 2 trial of certolizumab pegol, a new PEGylated anti-TNF agent, in the treatment of Crohn's disease - An interview with David A Schwartz, 13 June 20071177-54751177-5491https://doaj.org/article/08346a070d204e8d80f6d9eaca6f71952008-03-01T00:00:00Zhttp://www.dovepress.com/the-precise-2-trial-of-certolizumab-pegol-a-new-pegylated-anti-tnf-age-a61https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491David A SchwartzVanderbilt University Medical Center, Nashville, TN, USAContext: Certolizumab pegol (CDP 870) is a new anti-tumor necrosis factor (TNF) therapy currently in development for the treatment of Crohn’s disease, rheumatoid arthritis, and psoriasis. Certolizumab pegol is the first PEGylated biologic anti-TNF agent and has a high binding affinity for TNF. Dr. Schwartz was an investigator of the PRECiSE (PEGylated Antibody Fragment Evaluation in Crohn’s Disease Safety and Efficacy) 2 trial of certolizumab pegol in patients with Crohn’s disease.Keywords: certolizumab pegol, PRECiSE 2 trial, Crohn’s disease David A SchwartzDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 1, Pp 125-128 (2008) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine (General) R5-920 |
| spellingShingle |
Medicine (General) R5-920 David A Schwartz The PRECiSE 2 trial of certolizumab pegol, a new PEGylated anti-TNF agent, in the treatment of Crohn's disease - An interview with David A Schwartz, 13 June 2007 |
| description |
David A SchwartzVanderbilt University Medical Center, Nashville, TN, USAContext: Certolizumab pegol (CDP 870) is a new anti-tumor necrosis factor (TNF) therapy currently in development for the treatment of Crohn’s disease, rheumatoid arthritis, and psoriasis. Certolizumab pegol is the first PEGylated biologic anti-TNF agent and has a high binding affinity for TNF. Dr. Schwartz was an investigator of the PRECiSE (PEGylated Antibody Fragment Evaluation in Crohn’s Disease Safety and Efficacy) 2 trial of certolizumab pegol in patients with Crohn’s disease.Keywords: certolizumab pegol, PRECiSE 2 trial, Crohn’s disease |
| format |
article |
| author |
David A Schwartz |
| author_facet |
David A Schwartz |
| author_sort |
David A Schwartz |
| title |
The PRECiSE 2 trial of certolizumab pegol, a new PEGylated anti-TNF agent, in the treatment of Crohn's disease - An interview with David A Schwartz, 13 June 2007 |
| title_short |
The PRECiSE 2 trial of certolizumab pegol, a new PEGylated anti-TNF agent, in the treatment of Crohn's disease - An interview with David A Schwartz, 13 June 2007 |
| title_full |
The PRECiSE 2 trial of certolizumab pegol, a new PEGylated anti-TNF agent, in the treatment of Crohn's disease - An interview with David A Schwartz, 13 June 2007 |
| title_fullStr |
The PRECiSE 2 trial of certolizumab pegol, a new PEGylated anti-TNF agent, in the treatment of Crohn's disease - An interview with David A Schwartz, 13 June 2007 |
| title_full_unstemmed |
The PRECiSE 2 trial of certolizumab pegol, a new PEGylated anti-TNF agent, in the treatment of Crohn's disease - An interview with David A Schwartz, 13 June 2007 |
| title_sort |
precise 2 trial of certolizumab pegol, a new pegylated anti-tnf agent, in the treatment of crohn's disease - an interview with david a schwartz, 13 june 2007 |
| publisher |
Dove Medical Press |
| publishDate |
2008 |
| url |
https://doaj.org/article/08346a070d204e8d80f6d9eaca6f7195 |
| work_keys_str_mv |
AT davidaschwartz theprecise2trialofcertolizumabpegolanewpegylatedantitnfagentinthetreatmentofcrohnamp39sdiseaseaninterviewwithdavidaschwartz13june2007 AT davidaschwartz precise2trialofcertolizumabpegolanewpegylatedantitnfagentinthetreatmentofcrohnamp39sdiseaseaninterviewwithdavidaschwartz13june2007 |
| _version_ |
1718402083041837056 |